MaxCyte Q1 revenue $11.3M (+32% YoY); updates 2024 SPL guidance to ~$5M

MAXCYTE, INC.

Total revenue $11.3M, up 32% YoY; core revenue $8.2M, up 5%.
SPL program-related revenue $3.2M, up 292% YoY; four new SPLs signed YTD including Be Biopharma.
Net loss $9.5M vs $10.9M in Q1 2023; EBITDA loss $11.2M.
2024 guidance: core revenue flat to 5% growth; SPL revenue expected ~$5M (increase).
Cash and investments $202.5M at March 31; expects year-end cash at least $175M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAXCYTE, INC. reported the quarter ended March 31, 2024 results: revenue $11.3 million, net income $9.5 million. Guidance raised.

Period: the quarter ended March 31, 2024
Revenue: $11.3 million
Net income: $9.5 million
Guidance: raised
Result: reported results

Exact text from the filing

applications, today announced its first quarter ended March 31, 2024 financial results and updated its 2024 guidance. First Quarter Highlights · Total revenue of $11.3 million in the first quarter of 2024, an increase of 32% over the first quarter of 2023. · Core business revenue of $8.2 million in the first quarter of 2024, an increase of 5% over the

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-007051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.